In the Phase III INNOVATE-3 trial, Novocure’s investigational ovarian cancer therapy Tumor Treating Fields was unable to significantly improve overall survival, the company announced Monday.
A first-in-human Phase I trial showed that Eli Lilly’s investigational oral lipoprotein(a) inhibitor muvalaplin was safe and could elicit sharp reductions in concentrations of cholesterol formation.
Despite improvements in China, air pollution across the globe continues to pose the greatest external risk to human health, with countries in Asia and Africa suffering most of the impact, new research showed on Tuesday.
the Digital Medicine Society (DiMe) released findings from a digital health industry needs assessment to identify 1) the drivers of successful digital health product development and adoption, and 2) the regulatory policy needed to facilitate these drivers.
An Australian scientist detailed on Tuesday a world-first discovery after an 8-cm (3-inch) -long parasitic worm was found in the brain of a woman in Canberra, spotlighting the risks of infectious organisms jumping between species.
The late-stage results for acoramidis, BridgeBio’s transthyretin amyloid cardiomyopathy candidate, indicate significant survival, functional and biomarker improvements over placebo.
Novocure said today that its therapy failed in a late-stage trial to meet the main goal of improving survival rates in patients with a type of ovarian cancer.
The company said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson’s disease symptoms in an early 12-patient trial.
Novo Nordisk notched another win Friday as its mega blockbuster Wegovy (semaglutide) proved to also help patients with a common type of heart failure. The Danish pharma company announced results from a Phase III trial, published in The New England Journal of Medicine, adding to the drug’s growing list of benefits.
Merck & Co. and partner Eisai said on Friday they will shut down a late-stage study testing an experimental combination therapy for a type of head and neck cancer after an interim analysis showed it failed to prolong lives of patients.
